# US 2025/0082604 A1 · Compositions containing a high content of proanthocyanidins and methods of preparation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082604 A1
- Document ID: US20250082604A1
- Status: Published application
- Kind: A1
- Application number: 18/891,337
- Filed: 2024-09-20
- Published: 2025-03-13
- Earliest claimed: 2022-03-21
- Assignees: Tintoria Piana US, Inc.
- Applicants: Tintoria Piana, US Inc.
- Inventors: Massimo MAFFEI; Giuseppe MANNINO; Andrea PIANA
- Web page: https://patentgrep.com/patent/US20250082604A1

## CPC

- A01H 5/08: Fruits
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A01H 5/04: Stems
- A01H 5/10: Seeds
- A61K 36/15: Pinaceae (Pine family), e.g. pine or cedar
- A61K 36/45: Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K 36/87: Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- A61K 2236/51: Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
- A61K 2236/53: Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
- A01H: NEW PLANTS OR {NON-TRANSGENIC} PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A process of extracting proanthocyanidins (PACs) from plant materials using an ethanol or acetone solvent is described. Plant materials from one or more plant species are mixed with ethanol or acetone at a ratio of extraction solvent to plant material between 3:1 and 8:1. The mixture is then filtered and the filtrate concentrated by evaporation. The extraction process leads to an increase in the total PAC content and in the total A-type PAC content in the degree of polymerization from dimers to pentamers. Formulations containing such PAC-enriched compositions have antioxidant, antibiotic, and antiviral properties and have a negligible allergen content.

## Claims

### Claim 1

A formulation comprising PAC-enriched compositions extracted from each of Vitis vinifera, Arachis hypogaea, Pinus pinaster, Vaccinium vitis-idaea.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the formulation comprises
1-25 wt % Vitis vinifera PAC-enriched composition;
40-85 wt % Arachis hypogaea PAC-enriched composition;
1-35 wt % Pinus pinaster PAC-enriched composition; and
5-45 wt % Vaccinium vitis-idaea PAC-enriched composition.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the formulation contains 500-600 mg/g of PACs.

### Claim 4 (depends on 3)

The formulation of claim 3, wherein the formulation has a peanut allergen content of 1.5 μg or less.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the PAC-enriched compositions comprise dimeric, trimeric, tetrameric, and pentameric PACs.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the PAC-enriched compositions comprises a higher percentage of A-type PACs as compared to a percentage of A-type PACs in the plant material prior to extraction.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein each of the PAC-enriched compositions were extracted using 90-100 vol % ethanol or 90-100 vol % acetone.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the formulation is in a solid dosage form selected from a tablet, capsule, or softgel.

### Claim 9

A method for preparing a proanthocyanidin (PAC)-enriched composition, comprising
mixing a plant material containing PACs with an extraction solvent comprising 90-100 vol % ethanol or 90-100 vol % acetone to provide a mixture;
filtering the mixture to provide a filtrate; and
evaporating the filtrate to provide a dried PAC-enriched composition.

### Claim 10 (depends on 9)

The method of claim 9, further comprising crushing the dried PAC-enriched composition to provide a powder.

### Claim 11 (depends on 9)

The method of claim 9, wherein the plant material is obtained from one or more species selected from the group consisting of Vaccinium macrocarpon, Vitis vinifera, Arachis hypogaea, Pinus pinaster, Vaccinium vitis-idaea.

### Claim 12 (depends on 9)

The method of claim 9, wherein the extraction solvent further comprises an acid.

### Claim 13 (depends on 9)

The method of claim 9, wherein a ratio of extraction solvent to plant material is between 3:1 and 8:1.

### Claim 14 (depends on 9)

The method of claim 9, wherein the mixing step is performed for 10-60 minutes.

### Claim 15 (depends on 9)

The method of claim 9, wherein the mixing step is performed at a temperature of 10-30° C.

### Claim 16 (depends on 9)

The method of claim 9, wherein the evaporating step is performed using vacuum evaporation.

### Claim 17 (depends on 9)

The method of claim 9, wherein the evaporating step is performed using vacuum evaporation to provide a dense liquid followed by drying the dense liquid at a temperature of 40-90° C.

### Claim 18 (depends on 9)

The method of claim 9, wherein the evaporating step is performed via spray drying.

### Claim 19 (depends on 9)

The method of claim 9, wherein the PAC-enriched composition comprises dimeric, trimeric, tetrameric, and pentameric PACs.

### Claim 20 (depends on 9)

The method of claim 9, wherein the PAC-enriched composition comprises a higher percentage of A-type PACs as compared to a percentage of A-type PACs in the plant material prior to extraction.

### Claim 21 (depends on 9)

The method of claim 9, further comprising determining a PAC content in the plant material before the mixing step.

### Claim 22 (depends on 9)

A PAC-enriched composition prepared by the method of claim 9.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the composition is in a solid dosage form selected from a tablet, capsule, or softgel.

### Claim 24 (depends on 1)

A method of inhibiting replication of viral particles, comprising contacting the viral particles with the formulation of claim 1.

### Claim 25 (depends on 23)

The method of claim 23, wherein the viral particles are a virus selected from the group consisting of influenza virus, respiratory syncytial virus, coronavirus, ebola virus, and human immunodeficiency virus.

### Claim 26 (depends on 1)

A method of treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the formulation of claim 1.

### Claim 27 (depends on 26)

The method of claim 26, wherein the viral infection is caused by a virus selected from the group consisting of influenza virus, respiratory syncytial virus, coronavirus, ebola virus, and human immunodeficiency virus.

### Claim 28 (depends on 1)

A method of inhibiting adhesion of bacteria to cells, comprising contacting the bacteria with the formulation of claim 1.

### Claim 29 (depends on 28)

The method of claim 28, wherein the bacteria is selected from one or more of Escherichia coli, Coagulase negative Staphylococci, Enterococcus Spp., Helicobacter pilorii, Candida albicans, and Non-albicans Candida Spp.

### Claim 30 (depends on 1)

A method of treating a bacterial infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the formulation of claim 1.

### Claim 31 (depends on 30)

The method of claim 30, wherein the bacterial infection is a urinary tract infection caused by one or more of Escherichia coli, Coagulase negative Staphylococci, Enterococcus Spp., Helicobacter pilorii, Candida albicans, and Non-albicans Candida Spp.